Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

Background New treatments with new mechanisms are urgently needed for people with
schizophrenia. Xanomeline is a dual M 1 and M 4-preferring muscarinic receptor agonist …

Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

The mesolimbic hypothesis has been a central dogma of schizophrenia for decades,
positing that aberrant functioning of midbrain dopamine projections to limbic regions causes …

Background The muscarinic receptor agonist xanomeline has antipsychotic properties and
is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events …

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in
Alzheimer's disease and schizophrenia. We present data on the effect of KarXT (xanomeline …

Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …